Autoliv Inc. (NYSE:ALV) Is Doing The Institutional Rounds Once Again
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Autoliv Inc. (NYSE:ALV) reported that Alecta Pensionsforsakring, Omsesidigt has picked up 8,362,500 of common stock as of 2017-01-19.
The acquisition brings the aggregate amount owned by Alecta Pensionsforsakring, Omsesidigt to a total of 8,362,500 representing a 9.48% stake in the company.
For those not familiar with the company, Autoliv, Inc. is a developer, manufacturer and supplier to the automotive industry of automotive safety systems. The Company operates through two segments: Passive Safety and Electronics. Passive Safety segment includes airbags, seatbelts and steering wheels. Passive safety systems manage vehicle safety and include modules and components for passenger and driver-side airbags, side-impact airbag protection systems, seatbelts, steering wheels, inflator technologies, whiplash protection systems and child seats, and components for such systems passive safety electronic products, such as restraint electronics and crash sensors. Active safety systems intervene before a collision to make accidents avoidable or to reduce impact.
A glance at Autoliv Inc (NYSE:ALV)’s key stats reveals a current market capitalization of 9.89 billion based on 88.22 million shares outstanding and a price at last close of $113.66 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2012-02-28, Nyberg picked up 2,000 at a purchase price of $68.14. This brings their total holding to 5,000 as of the date of the filing.
On the sell side, the most recent transaction saw Alspaugh unload 647 shares at a sale price of $112.21. This brings their total holding to 3,800.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Autoliv Inc. (NYSE:ALV) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Genius Brands International Inc. (NASDAQ:GNUS) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Genius Brands International Inc. (NASDAQ:GNUS) reported that Sony Corp has picked up 301,231 of common stock as of 2017-01-19.
The acquisition brings the aggregate amount owned by Sony Corp to a total of 301,231 representing a 7.0% stake in the company.
For those not familiar with the company, Genius Brands International, Inc. is a content and brand management company. The Company provides entertaining and enriching content and products with a purpose for toddlers to tweens. The Company produces original content and licenses the rights to that content to a range of partners. Its licensees include companies to which the audio-visual rights are licensed for exhibition in various formats, such as Pay Television, Free or Broadcast Television, video-on-demand (VOD), subscription on demand (SVOD) and digital video discs/compact discs (DVDs/CDs), and companies that develop and distribute products based on its content within different product categories, such as toys, electronics, publishing, home goods, stationary and gifts.
A glance at Genius Brands International Inc. (NASDAQ:GNUS)’s key stats reveals a current market capitalization of 20.09 million based on 3.99 million shares outstanding and a price at last close of $5.00 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-16, Payne picked up 250 at a purchase price of $1.00. This brings their total holding to 250 as of the date of the filing.
On the sell side, the most recent transaction saw Balaban unload 312,500 shares at a sale price of $0.08. This brings their total holding to 10,421,424.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Genius Brands International Inc. (NASDAQ:GNUS) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Park West Is Buying Kindred Biosciences Inc. (NASDAQ:KIN) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Kindred Biosciences Inc. (NASDAQ:KIN) reported that Park West Asset Management has picked up 3,964,138 of common stock as of 2017-01-19.
The acquisition brings the aggregate amount owned by Park West Asset Management to a total of 3,964,138 representing a 19.9% stake in the company.
For those not familiar with the company, Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company’s product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company’s lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats.
A glance at Kindred Biosciences Inc. (NASDAQ:KIN)’s key stats reveals a current market capitalization of 132.54 million based on 19.92 million shares outstanding and a price at last close of $6.45 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-13, Park picked up 1,690,000 at a purchase price of $6.20. This brings their total holding to 3,964,138 as of the date of the filing.
On the sell side, the most recent transaction saw Park unload 18,000 shares at a sale price of $4.78. This brings their total holding to 1,989,084.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Kindred Biosciences Inc. (NASDAQ:KIN) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Sunshine Heart Inc. (NASDAQ:SSH) Attracts Yet More Smart Money
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Sunshine Heart Inc. (NASDAQ:SSH) reported that Talu Ventures Pty Ltd has picked up 634,817 of common stock as of 2017-01-19.
The acquisition brings the aggregate amount owned by Talu Ventures Pty Ltd to a total of 634,817 representing a 2.7% stake in the company.
For those not familiar with the company, Sunshine Heart is a global medical device company founded by a cardiac surgeon that saw an incredible opportunity for how to treat heart failure. Heart failure (HF) affects millions and is a progressive condition that prevents patients from living normal lives. Sunshine Heart’s C-Pulse® Heart Assist System has CE Mark in Europe and is in a clinical study in the United States to determine if the C-Pulse System is safe and effective for treating moderate to severe heart failure. C-Pulse therapy is designed to reduce overall heart failure symptoms, improve quality of life, and reduce re-hospitalizations.
A glance at Sunshine Heart Inc. (NASDAQ:SSH)’s key stats reveals a current market capitalization of 5.57 million based on 776,000.00 shares outstanding and a price at last close of $7.65 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-11-28, Erb picked up 80,000 at a purchase price of $0.22. This brings their total holding to 464,128 as of the date of the filing.
On the sell side, the most recent transaction saw Peters unload 5,000 shares at a sale price of $5.47. This brings their total holding to 11,384.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Sunshine Heart Inc. (NASDAQ:SSH) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Icahn Is Buying Federal-Mogul Holdings Corp (NASDAQ:FDML) Shares
There are worse backers to have than the Icahn estate, and an announcement detailing that said estate has just taken a position in your future can be a strong upside catalyst for any company. Federal just found this out.
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Federal-Mogul Holdings Corp (NASDAQ:FDML) reported that Icahn Capital LP has picked up 138,590,141 of common stock as of 2017-01-18.
The acquisition brings the aggregate amount owned by Icahn Capital LP to a total of 138,590,141 representing a 82.0% stake in the company.
For those not familiar with the company, Federal-Mogul Holdings Corporation is a supplier of technology in vehicle and industrial products for fuel economy, emissions reduction and safety systems. The Company operates in two segments: Powertrain segment and Motorparts segment. The Powertrain segment focuses on original equipment products for automotive, heavy duty and industrial applications. The Motorparts segment sells and distributes a portfolio of products in the global aftermarket. The Company supplies a range of components, accessories and systems. The Company serves the original equipment manufacturers (OEM) and original equipment servicers (OES) (collectively OE) of automotive, light, medium and heavy-duty commercial vehicles, off-road, agricultural, marine, rail, aerospace, power generation and industrial equipment.
A glance at Federal-Mogul Holdings Corp (NASDAQ:FDML)’s key stats reveals a current market capitalization of 1.66 billion based on 169.04 million shares outstanding and a price at last close of $9.87 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2013-04-26, Jueckstock picked up 40 at a purchase price of $6.79. This brings their total holding to 40 as of the date of the filing.
On the sell side, the most recent transaction saw Goachet unload 13,800 shares at a sale price of $14.45. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Federal-Mogul Holdings Corp (NASDAQ:FDML) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Loxo Oncology Inc. (NASDAQ:LOXO) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Loxo Oncology Inc. (NASDAQ:LOXO) reported that Access Industries Management, Llc. has picked up 2,080,897 of common stock as of 2017-01-18.
The acquisition brings the aggregate amount owned by Access Industries Management, Llc. to a total of 2,080,897 representing a 8.15% stake in the company.
For those not familiar with the company, Loxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity.
A glance at Loxo Oncology Inc. (NASDAQ:LOXO)’s key stats reveals a current market capitalization of 947.01 million based on 25.55 million shares outstanding and a price at last close of $37.61 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-01-10, Aisling picked up 160,000 at a purchase price of $31.00. This brings their total holding to 4,188,920 as of the date of the filing.
On the sell side, the most recent transaction saw Flaherty unload 7,250 shares at a sale price of $30.23. This brings their total holding to 38,732.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Loxo Oncology Inc. (NASDAQ:LOXO) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Ardelyx Inc. (NASDAQ:ARDX) Is An In Demand Biotech
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ardelyx Inc. (NASDAQ:ARDX) reported that Future Fund Board Of Guardians has picked up 3,436,426 of common stock as of 2017-01-18.
The acquisition brings the aggregate amount owned by Future Fund Board of Guardians to a total of 3,436,426 representing a 7.3% stake in the company.
For those not familiar with the company, Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally systemic therapeutic drugs that work in the gastrointestinal (GI) tract to treat GI and cardio-renal diseases. The Company operates through research, development and commercialization of biopharmaceutical products segment. It has discovered and designed its lead product candidate, tenapanor, which is a minimally systemic small molecule that acts locally in the GI tract to inhibit the sodium transporter sodium-hydrogen exchanger 3 (NHE3) and reduce sodium and phosphorus uptake from the gut. It is evaluating tenapanor in over two pivotal Phase III clinical studies in patients with constipation-predominant irritable bowel syndrome (IBS-C). It is developing RDX022 for the treatment of hyperkalemia.
A glance at Ardelyx Inc. (NASDAQ:ARDX)’s key stats reveals a current market capitalization of 690.34 million based on 47.30 million shares outstanding and a price at last close of $13.80 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-07-18, Weller picked up 763,650 at a purchase price of $8.73. This brings their total holding to 2,665,519 as of the date of the filing.
On the sell side, the most recent transaction saw Rosenbaum unload 900 shares at a sale price of $14.48. This brings their total holding to 636.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ardelyx Inc. (NASDAQ:ARDX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Here’s Who Just Picked Up Fifth Street Asset Management Inc. (NASDAQ:FSAM) Shares
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Fifth Street Asset Management Inc. (NASDAQ:FSAM) reported that Springhouse Capital (master), L.p. has picked up 537,402 of common stock as of 2017-01-18.
The acquisition brings the aggregate amount owned by Springhouse Capital (master), L.p. to a total of 537,402 representing a 8.14% stake in the company.
For those not familiar with the company, Fifth Street Asset Management Inc. is an alternative asset manager. The Company provides asset management services to its investment funds (the Fifth Street Funds or the funds), which consist of Fifth Street Finance Corp. (FSC) and Fifth Street Senior Floating Rate Corp. (FSFR), both publicly-traded business development companies (together, the BDCs). Its segment provides asset management services to the Fifth Street Funds. The Company conducts all of its operations through its subsidiaries, Fifth Street Management LLC (FSM), Fifth Street CLO Management LLC (CLO Management) and FSCO GP LLC (FSCO GP). The funds, managed by the Company, provide financing solutions to small and mid-sized companies across their capital structures, mainly in connection with investments by private equity sponsors. It provides credit solutions across the capital structure, including one-stop financing, unitranche debt, senior secured debt, mezzanine debt, equity co-investments and venture debt financing.
A glance at Fifth Street Asset Management Inc. (NASDAQ:FSAM)’s key stats reveals a current market capitalization of 47.98 million based on 6.60 million shares outstanding and a price at last close of $7.00 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-01-15, Mangrove picked up 196,531 at a purchase price of $2.44. This brings their total holding to 696,738 as of the date of the filing.
On the sell side, the most recent transaction saw August unload 5,648 shares at a sale price of $5.28. This brings their total holding to 20,000.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Fifth Street Asset Management Inc. (NASDAQ:FSAM) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.